Warning! GuruFocus detected
2 Severe warning signs
with SUS.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Surgical Science Sweden AB
ISIN : SE0014428512
Compare
Compare
Traded in other countries / regions
SUS.SwedenSUSRF.USA4P41.Germany IPO Date
2017-06-19Description
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments; Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations, prior to entering the clinical environment and also support and services, and Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments and also simulators for medical device companies.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.11 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 1.63 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.83 | |||||
| Beneish M-Score | -2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.3 | |||||
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 8.5 | |||||
| 3-Year FCF Growth Rate | 44.8 | |||||
| 3-Year Book Growth Rate | 10.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 45.97 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 20.52 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.45 | |||||
| 9-Day RSI | 36.97 | |||||
| 14-Day RSI | 34.99 | |||||
| 3-1 Month Momentum % | 0.06 | |||||
| 6-1 Month Momentum % | 28.18 | |||||
| 12-1 Month Momentum % | 8.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.14 | |||||
| Quick Ratio | 4.49 | |||||
| Cash Ratio | 3.49 | |||||
| Days Inventory | 218.04 | |||||
| Days Sales Outstanding | 48.64 | |||||
| Days Payable | 52.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -2.93 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.63 | |||||
| Operating Margin % | 16.32 | |||||
| Net Margin % | 14.89 | |||||
| FCF Margin % | 10.15 | |||||
| ROE % | 2.89 | |||||
| ROA % | 2.64 | |||||
| ROIC % | 2.83 | |||||
| 3-Year ROIIC % | 5.18 | |||||
| ROC (Joel Greenblatt) % | 120.22 | |||||
| ROCE % | 3.05 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 51.87 | |||||
| Forward PE Ratio | 31.99 | |||||
| PE Ratio without NRI | 51.87 | |||||
| Shiller PE Ratio | 90.02 | |||||
| Price-to-Owner-Earnings | 173.15 | |||||
| PEG Ratio | 1.67 | |||||
| PS Ratio | 7.74 | |||||
| PB Ratio | 1.41 | |||||
| Price-to-Tangible-Book | 7.58 | |||||
| Price-to-Free-Cash-Flow | 76.16 | |||||
| Price-to-Operating-Cash-Flow | 49.74 | |||||
| EV-to-EBIT | 42.22 | |||||
| EV-to-Forward-EBIT | 23.25 | |||||
| EV-to-EBITDA | 42.22 | |||||
| EV-to-Forward-EBITDA | 17.91 | |||||
| EV-to-Revenue | 6.91 | |||||
| EV-to-Forward-Revenue | 5.15 | |||||
| EV-to-FCF | 66.3 | |||||
| Price-to-GF-Value | 0.7 | |||||
| Price-to-Projected-FCF | 1.38 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.07 | |||||
| Price-to-Graham-Number | 4.18 | |||||
| Price-to-Net-Current-Asset-Value | 8.81 | |||||
| Price-to-Net-Cash | 21.55 | |||||
| Earnings Yield (Greenblatt) % | 2.36 | |||||
| FCF Yield % | 1.32 | |||||
| Forward Rate of Return (Yacktman) % | 21.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Surgical Science Sweden AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 884.086 | ||
| EPS (TTM) (kr) | 2.58 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.08 | ||
| Volatility % | 30.32 | ||
| 14-Day RSI | 34.99 | ||
| 14-Day ATR (kr) | 5.907986 | ||
| 20-Day SMA (kr) | 141.32 | ||
| 12-1 Month Momentum % | 8.67 | ||
| 52-Week Range (kr) | 111.8 - 192.4 | ||
| Shares Outstanding (Mil) | 51.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Surgical Science Sweden AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Surgical Science Sweden AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Surgical Science Sweden AB Frequently Asked Questions
What is Surgical Science Sweden AB(OSTO:SUS)'s stock price today?
The current price of OSTO:SUS is kr133.80. The 52 week high of OSTO:SUS is kr192.40 and 52 week low is kr111.80.
When is next earnings date of Surgical Science Sweden AB(OSTO:SUS)?
The next earnings date of Surgical Science Sweden AB(OSTO:SUS) is 2025-05-14.
Does Surgical Science Sweden AB(OSTO:SUS) pay dividends? If so, how much?
Surgical Science Sweden AB(OSTO:SUS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers